CEOs around the world believe that economic growth will be better - दुनिया भर के सीईओ को आर्थिक वृद्धि बेहतर रहने का भरोसा
livehindustan.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from livehindustan.com Daily Mail and Mail on Sunday newspapers.
Malaria: Infections halved in children in Ivory Coast using new technology
Malaria is a leading cause of death for children and is most prevalent in some of the world s poorest countries. A new lure-and-kill style device trial shows potential for a major drop in malaria-spreading mosquitoes.
Malaria is a leading cause of death among children worldwide
A new type of malaria control has significantly brought down infection rates among children in the Ivory Coast in western Africa, according to new research published in The Lancet.
The device, developed by Dutch researchers and trialed over two years in combination with the use of window screens and insecticide-coated bed nets, was found to lower the incidence of malaria by around 40% to 50% in children aged between six months and 10 years old.
Britain’s vaccine gamble
By Sanjeev Krishna and Yolanda Augustin
LONDON The British have often taken great pride in dubious achievements, from the “victorious” retreat from Dunkirk during World War II to the bare-minimum Brexit agreement recently reached with the European Union. The development of a COVID-19 vaccine on British soil, however, was a genuine triumph. And yet, by delaying the delivery of second vaccine doses, the government is set to undercut this feat, and its overall pandemic-containment strategy.
The manufacturers of all three vaccines so far approved in the United Kingdom, the homegrown AstraZeneca/University of Oxford DNA vaccine, and the Pfizer/BioNTech and Moderna mRNA vaccines, recommend delivering the second dose 3-4 weeks after the first. And yet the UK government has decided to leave a 12-week gap between doses.
January 12, 2021
BEDFORDSHIRE, UK December 24, 2020 Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, is pleased to announce its professional-use COVID-19 Rapid Antigen Test has been certified with a CE mark, following independent assessment by the Liverpool School of Tropical Medicine (LSTM). The test will provide health professionals an accurate detection of the nucleoprotein of the SARS-CoV-2 virus in respiratory swabs, within 10 minutes. Development and validation were supported by the Wellcome Trust and the Foreign, Commonwealth and Development Office (FCDO) Joint Initiative on Research in Epidemic Preparedness and Response. The urgency for affordable diagnostics that are quality assured has been highlighted by the need to free people from quarantine and enable travel, commented professor Sanjeev Krishna, St George s University of London. Working within a consortium with Mologic and academic partners has been one of the most effective w
vimarsana © 2020. All Rights Reserved.